BioAge taps European biobank for human aging data

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Company aims to enhance drug discovery by observing the molecular changes that occur as people transition from health to disease over decades.

Longevity biotech BioAge Labs has announced that it will harness molecular data from the HUNT Biobank in Norway to expand the capabilities of its drug discovery platform. By analyzing biological samples gathered from more than 6,000 participants in the HUNT study, one of Europe’s largest and most extensively characterized population health cohorts, the company aims to generate millions of molecular readouts that will deepen its understanding of the biological mechanisms that support resilience and influence the development of aging-related diseases.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Beauty giant and supplement startup both chase skin aging

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE